Abiopharma

General Announcement: CONVERSION AND CANCELLATION OF CONVERTIBLE BONDS

European Commission Approves KEYTRUDA®(pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Net Asset Value(s)

BOSS Zhipins Ongoing Share Repurchases Reach Nearly RMB1.94 Billion in 2026

Brightstar Lottery to Enhance Retail Technology for Oregon Lottery via Five-Year Contract Extension

Spire Global Delivers 10 Satellites to Vandenberg Space Force Base Ahead of the Transporter-17 Rideshare Mission

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

BRAND BOND 3 - technical error on record date for a partial redemption, error corrected, trade will be resume after halt trade